Laboratorios Farmaceuticos Rovi Future Growth
Future criteria checks 4/6
Laboratorios Farmaceuticos Rovi is forecast to grow earnings and revenue by 16.6% and 8.7% per annum respectively. EPS is expected to grow by 14.8% per annum. Return on equity is forecast to be 29.8% in 3 years.
Key information
16.6%
Earnings growth rate
14.8%
EPS growth rate
Pharmaceuticals earnings growth | 14.7% |
Revenue growth rate | 8.7% |
Future return on equity | 29.8% |
Analyst coverage | Good |
Last updated | 26 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,039 | 267 | 215 | 245 | 7 |
12/31/2025 | 906 | 206 | 163 | 202 | 7 |
12/31/2024 | 824 | 171 | 156 | 192 | 5 |
12/31/2023 | 830 | 170 | 58 | 113 | N/A |
9/30/2023 | 837 | 197 | 60 | 120 | N/A |
6/30/2023 | 818 | 186 | 61 | 121 | N/A |
3/31/2023 | 814 | 194 | 104 | 158 | N/A |
12/31/2022 | 818 | 200 | 186 | 238 | N/A |
9/30/2022 | 761 | 176 | 144 | 182 | N/A |
6/30/2022 | 739 | 183 | 192 | 232 | N/A |
3/31/2022 | 724 | 182 | 190 | 229 | N/A |
12/31/2021 | 649 | 153 | 109 | 149 | N/A |
9/30/2021 | 581 | 113 | 145 | 189 | N/A |
6/30/2021 | 519 | 82 | 105 | 149 | N/A |
3/31/2021 | 450 | 71 | 31 | 72 | N/A |
12/31/2020 | 420 | 61 | 7 | 47 | N/A |
9/30/2020 | 413 | 55 | -37 | -7 | N/A |
6/30/2020 | 395 | 53 | -52 | -27 | N/A |
3/31/2020 | 400 | 46 | -34 | -7 | N/A |
12/31/2019 | 381 | 39 | -50 | -9 | N/A |
9/30/2019 | 355 | 33 | -39 | 6 | N/A |
6/30/2019 | 334 | 27 | -31 | 12 | N/A |
3/31/2019 | 310 | 18 | -38 | 3 | N/A |
12/31/2018 | 303 | 18 | -18 | 9 | N/A |
9/30/2018 | 291 | 16 | -13 | 8 | N/A |
6/30/2018 | 283 | 9 | -4 | 16 | N/A |
3/31/2018 | 284 | 18 | 10 | 30 | N/A |
12/31/2017 | 276 | 17 | -2 | 18 | N/A |
9/30/2017 | 277 | 22 | N/A | 21 | N/A |
6/30/2017 | 275 | 24 | N/A | 25 | N/A |
3/31/2017 | 272 | 23 | N/A | 24 | N/A |
12/31/2016 | 265 | 26 | N/A | 46 | N/A |
9/30/2016 | 260 | 25 | N/A | 44 | N/A |
6/30/2016 | 254 | 24 | N/A | 38 | N/A |
3/31/2016 | 246 | 23 | N/A | 40 | N/A |
12/31/2015 | 246 | 20 | N/A | 29 | N/A |
9/30/2015 | 242 | 21 | N/A | 22 | N/A |
6/30/2015 | 243 | 23 | N/A | 27 | N/A |
3/31/2015 | 241 | 25 | N/A | 29 | N/A |
12/31/2014 | 238 | 24 | N/A | 23 | N/A |
9/30/2014 | 230 | 24 | N/A | 30 | N/A |
6/30/2014 | 224 | 24 | N/A | 28 | N/A |
3/31/2014 | 221 | 24 | N/A | 20 | N/A |
12/31/2013 | 218 | 23 | N/A | 30 | N/A |
9/30/2013 | 209 | 22 | N/A | 19 | N/A |
6/30/2013 | 207 | 20 | N/A | 17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0ILL's forecast earnings growth (16.6% per year) is above the savings rate (1.6%).
Earnings vs Market: 0ILL's earnings (16.6% per year) are forecast to grow faster than the UK market (12.2% per year).
High Growth Earnings: 0ILL's earnings are forecast to grow, but not significantly.
Revenue vs Market: 0ILL's revenue (8.7% per year) is forecast to grow faster than the UK market (3.3% per year).
High Growth Revenue: 0ILL's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0ILL's Return on Equity is forecast to be high in 3 years time (29.8%)